CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy for Relapsed/Refractory B Cell Non-Hodgkin Lymphoma (ANTLER)
NCT ID: NCT04637763
Last Updated: 2025-03-24
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
PHASE1
72 participants
INTERVENTIONAL
2021-05-26
2025-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
CLBR001 and SWI019 in Patients With Relapsed / Refractory B-cell Malignancies
NCT04450069
Umbilical Cord Blood NK Cells, Rituximab, High-Dose Chemotherapy, and Stem Cell Transplant in Treating Patients With Recurrent or Refractory B-Cell Non-Hodgkin's Lymphoma
NCT03019640
Allogenic CD19-targeting CAR-γδT Cell Therapy in R/R NHL
NCT05554939
Rituximab, Prednisone, Cyclophosphamide, Doxorubicin, Vincristine, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Previously Untreated Mantle Cell Lymphoma
NCT00070447
A Study of Obinutuzumab(GA101) in Combination With High-Dose Methylprednisolone(HDMP) in Chronic Lymphocytic Leukemia(CLL) Patients (GA101 & HDMP)
NCT02229422
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
SINGLE_GROUP
(Part B) Expansion portion patients will receive CB-010 at the dose determined in Part A.
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Dose Escalation of CB-010
Patients with relapsed or refractory non-Hodgkin lymphoma will receive CB-010 following lymphodepletion.
CB-010
CB-010 is a CRISPR-edited allogeneic CAR-T cell therapy targeting CD19.
Cyclophosphamide
Chemotherapy for lymphodepletion
Fludarabine
Chemotherapy for lymphodepletion
Expansion of CB-010
Patients with relapsed or refractory non-Hodgkin lymphoma will receive CB-010 following lymphodepletion.
CB-010
CB-010 is a CRISPR-edited allogeneic CAR-T cell therapy targeting CD19.
Cyclophosphamide
Chemotherapy for lymphodepletion
Fludarabine
Chemotherapy for lymphodepletion
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
CB-010
CB-010 is a CRISPR-edited allogeneic CAR-T cell therapy targeting CD19.
Cyclophosphamide
Chemotherapy for lymphodepletion
Fludarabine
Chemotherapy for lymphodepletion
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Documented diagnosis of relapsed or refractory non-Hodgkin lymphoma after prior standard of care
* Eastern Cooperative Oncology Group performance status 0 or 1
* Adequate hematologic, renal, liver, cardiac and pulmonary organ function
Exclusion Criteria
* Active or chronic graft versus host disease requiring therapy
* Prior allogeneic stem cell transplantation
* Central nervous system (CNS) lymphoma, prior CNS malignancy
* Prior seizure disorder, cerebrovascular ischemia, dementia, cerebellar disease or autoimmune disease with CNS involvement.
* Primary immunodeficiency
* Current or expected need for systemic corticosteroid therapy
* Current thyroid disorder. Hypothyroidism controlled with stable hormone replacement is permitted
* Other malignancy within 2 years of study entry, except curatively treated malignancies or malignancies with low risk of recurrence
* Unwillingness to follow extended safety monitoring
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Caribou Biosciences, Inc.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of Alabama at Birmingham
Birmingham, Alabama, United States
Banner MD Anderson Cancer Center
Gilbert, Arizona, United States
HonorHealth
Scottsdale, Arizona, United States
University of Arizona Cancer Center
Tucson, Arizona, United States
University of Arkansas
Little Rock, Arkansas, United States
University of California San Diego Moores Cancer Center
La Jolla, California, United States
University of Southern California, Norris Comprehensive Cancer Center
Los Angeles, California, United States
Chao Family Comprehensive Cancer Center/University of California Irvine
Orange, California, United States
Advent Health
Orlando, Florida, United States
Bone and Marrow Transplant Group of Georgia
Atlanta, Georgia, United States
Georgia Cancer Center at Augusta University
Augusta, Georgia, United States
Holden Comprehensive Cancer Center at the University of Iowa
Iowa City, Iowa, United States
University of Kentucky Markey Cancer
Lexington, Kentucky, United States
Norton Cancer Institute
Louisville, Kentucky, United States
Tufts Medical Center
Boston, Massachusetts, United States
Hackensack Medical Center
Hackensack, New Jersey, United States
Atlantic Health System
Morristown, New Jersey, United States
Nyu Langone Health
New York, New York, United States
Montefiore Medical Center
The Bronx, New York, United States
Oncology Hematology Care
Cincinnati, Ohio, United States
Ohio State University James Cancer Hospital
Columbus, Ohio, United States
Oregon Health & Science University
Portland, Oregon, United States
University of Pennsylvania
Philadelphia, Pennsylvania, United States
Vanderbilt University Medical Center
Nashville, Tennessee, United States
Baylor Charles A. Sammons Cancer Center
Dallas, Texas, United States
MD Anderson Cancer Center
Houston, Texas, United States
Huntsman Cancer Institute at the University of Utah
Salt Lake City, Utah, United States
Virginia Oncology Associates
Norfolk, Virginia, United States
Virginia Commonwealth University (VCU)
Richmond, Virginia, United States
Swedish Cancer Institute
Seattle, Washington, United States
Medical College of Wisconsin
Milwaukee, Wisconsin, United States
Westmead Hospital
Westmead, New South Wales, Australia
Epworth Healthcare
Richmond, Victoria, Australia
Royal Perth Hospital
Perth, Western Australia, Australia
Hadassah Medical Center
Jerusalem, , Israel
Rabin Medical Center
Petah Tikva, , Israel
Tel Aviv Medical Center
Tel Aviv, , Israel
The Sheba Fund for Health Services and Research (R.A.)
Tel Litwinsky, , Israel
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CB10A
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.